GRCE Grace Therapeutics Inc.
Price (delayed)
$2.31
Market cap
$23.42M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$12.37M
Highlights
The debt has shrunk by 100% YoY
The EPS has surged by 77% year-on-year but it has declined by 15% since the previous quarter
Grace Therapeutics's net income has soared by 66% YoY but it has decreased by 15% from the previous quarter
Grace Therapeutics's quick ratio has shrunk by 61% YoY
The company's equity fell by 19% YoY and by 7% QoQ
Key stats
What are the main financial stats of GRCE
Market
Valuations
Earnings
Shares outstanding
10.14M
Market cap
$23.42M
Enterprise value
$12.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.76M
Net income
-$13.37M
EBIT
-$16.92M
EBITDA
-$16.92M
Free cash flow
-$14.06M
Per share
Balance sheet
Liquidity
EPS
-$1.16
EPS diluted
-$1.16
Free cash flow per share
-$1.22
Book value per share
$5.14
Revenue per share
$0
TBVPS
$1.04
Total assets
$61.22M
Total liabilities
$9.09M
Debt
$0
Equity
$52.14M
Working capital
$9.97M
Debt to equity
0
Current ratio
6.06
Quick ratio
5.76
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-19.8%
Return on equity
-23.3%
Return on invested capital
N/A
Return on capital employed
-28.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GRCE stock price
How has the Grace Therapeutics stock price performed over time
Intraday
2.21%
1 week
-4.15%
1 month
-23.76%
1 year
-32.65%
YTD
-38.24%
QTD
1.32%
Financial performance
How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.76M
Net income
-$13.37M
Gross margin
N/A
Net margin
N/A
Grace Therapeutics's net income has soared by 66% YoY but it has decreased by 15% from the previous quarter
GRCE's operating income has soared by 65% year-on-year but it is down by 4.1% since the previous quarter
Growth
What is Grace Therapeutics's growth rate over time
Valuation
What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 77% year-on-year but it has declined by 15% since the previous quarter
The stock's P/B is 51% below its 5-year quarterly average of 0.9 and 27% below its last 4 quarters average of 0.6
The company's equity fell by 19% YoY and by 7% QoQ
Efficiency
How efficient is Grace Therapeutics business performance
The ROA has soared by 61% YoY but it has contracted by 21% from the previous quarter
The ROE has soared by 60% YoY but it has contracted by 21% from the previous quarter
Dividends
What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GRCE.
Financial health
How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has shrunk by 61% YoY
The company's current ratio has shrunk by 60% YoY
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
The company's equity fell by 19% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.